Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy by Guojun Chen et al.
Chen et al. Journal of Translational Medicine 2013, 11:21
http://www.translational-medicine.com/content/11/1/21RESEARCH Open AccessNeural stem cell-like cells derived from
autologous bone mesenchymal stem cells for the
treatment of patients with cerebral palsy
Guojun Chen1†, Yali Wang1†, Zhenyu Xu2†, Feng Fang1, Renmei Xu1, Yue Wang2, Xiaoli Hu2, Lixing Fan2
and Houqi Liu2*Abstract
Background: Stem cell therapy is a promising treatment for cerebral palsy, which refers to a category of brain
diseases that are associated with chronic motor disability in children. Autologous MSCs may be a better cell source
and have been studied for the treatment of cerebral palsy because of their functions in tissue repair and the
regulation of immunological processes.
Methods: To assess neural stem cell–like (NSC-like) cells derived from autologous marrow mesenchymal stem cells
as a novel treatment for patients with moderate-to-severe cerebral palsy, a total of 60 cerebral palsy patients were
enrolled in this open-label, non-randomised, observer-blinded controlled clinical study with a 6-months follow-up.
For the transplantation group, a total of 30 cerebral palsy patients received an autologous NSC-like cells
transplantation (1-2 × 107 cells into the subarachnoid cavity) and rehabilitation treatments whereas 30 patients in
the control group only received rehabilitation treatment.
Results: We recorded the gross motor function measurement scores, language quotients, and adverse events up to
6 months post-treatment. The gross motor function measurement scores in the transplantation group were
significantly higher at month 3 (the score increase was 42.6, 95% CI: 9.8–75.3, P=.011) and month 6 (the score
increase was 58.6, 95% CI: 25.8–91.4, P=.001) post-treatment compared with the baseline scores. The increase in the
Gross Motor Function Measurement scores in the control group was not significant. The increases in the language
quotients at months 1, 3, and 6 post-treatment were not statistically significant when compared with the baseline
quotients in both groups. All the 60 patients survived, and none of the patients experienced serious adverse events
or complications.
Conclusion: Our results indicated that NSC-like cells are safe and effective for the treatment of motor deficits
related to cerebral palsy. Further randomised clinical trials are necessary to establish the efficacy of this procedure.
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Childhood cerebral palsy is a non-progressive brain disease
that results from various cerebral insults that can occur
before birth and 1 month after birth. Patients primarily
present with motor developmental delay or motor dysfunc-
tion and possible mental retardation, epilepsy, behavioural
disorders, and sensory and perceptual disturbances.
Hypoxic ischemic encephalopathy and premature cerebral
palsy are the most common causes of cerebral palsy [1,2].
A census conducted in six cities in 1998 revealed that the
prevalence of cerebral palsy in children 1 to 6 years of age
was 1.92% [3]. The incidence of cerebral palsy in pre-
schoolers in the United States has ranged from 3%–4% [4].
Children with cerebral palsy may impart a heavy burden on
their families and society. Conventional therapies for treat-
ing cerebral palsy include physical therapy, motor function
training, language training, orthomorphia, neurotomy, and
intramuscular injections of botulinum toxin A. However,
these methods have not improved cerebral injuries in
patients with moderate-to-severe cerebral palsy [5,6].
Stem cell transplantation is a novel and promising treat-
ment for cerebral palsy [7,8]. However, this procedure is
still in the initial stages of investigation [9], and there have
not been any published results from clinical trials to date
[10]. Several types of stem cells are candidates for the
treatment of cerebral palsy, such as human embryonic
neural stem cells, olfactory ensheathing cells, umbilical
mesenchymal stem cells, and bone marrow MSCs
[7,8,11,12]. However, human embryonic neural stem cells
and olfactory ensheathing cells are difficult to apply in
clinical practice due to the potential immunological rejec-
tion of xenogenic cells, ethical arguments, a high risk of
transplantation within the brain, and the difficulty of
repeated transplantations [9]. Autologous MSCs may be a
better cell source and have been studied for the treatment
of cerebral palsy because of their functions in tissue repair
and the regulation of immunological processes [13]. In
addition, previous studies have demonstrated that human
bone marrow MSCs exhibit neural phenotypes and can
differentiate into NSC-like cells in vitro [14-16]. Moreover,
intraspinal cell therapy has led to better outcomes for
neurological disorders in animal-based studies [17,18] and
clinical trails [19,20]. Therefore, we hypothesized that an
intraspinal infusion of autologous MSCs-derived NSC-like
cells may be a novel treatment for patients with moderate-
to-severe cerebral palsy. In a controlled clinical study, we
investigated the clinical outcomes of 30 cerebral palsy
patients who underwent transplantation with NSC-like
cells and who were followed up for 6 months.
Methods
Study design and patient enrolment
An open-label, non-randomised, observer-blinded con-
trolled clinical study was conducted. The study wasapproved by the Ethics Committee and the Science Com-
mittee of the Armed Police General Hospital of Zhejiang
Province, China and was registered in the China Clinical
Trial Registry (ChiCTR-TRC-12002056). Informed con-
sent was obtained from all of the patients or their parents.
A total of 60 patients with cerebral palsy with Gross
Motor Function Classification System (GMFCS, corre-
sponding to GMFCS E&R 2007) levels III-V were enrolled
in this study from June 2010 to June 2011. Overall, 30
patients were treated with conventional methods and stem
cell transplantation and were included in the transplant-
ation group. An additional 30 patients with cerebral palsy
were only treated with conventional methods and were
included in the control group. The study protocol is
shown in Figure 1.
The patients were enrolled according to the following
inclusion criteria [3]: (1) the presence of non-progressive,
neurological disorders that appeared in infancy or early
childhood; (2) the appearance of retardation including
the lack of development or ability in sporting activities
and the persistence of posture obstacles, which may be
associated with lesions that affect feeling, perception, cog-
nition, communication, and behaviour, epilepsy or second-
ary musculoskeletal problems; (3) no diagnosis of other
diseases, such as metabolic or degenerative diseases, that
could induce central paralysis and transient retardation in
a normal person; and (4) negative serological markers for
AIDS, hepatitis, and syphilis. Patients with severe anaphyl-
actic or autoimmune diseases were excluded from the
transplantation group.
Autologous MSC cultures
Patients fasted for 4–6 hours and went without water 1
hour before the collection of autologous bone marrow
specimens. The patients were injected with 5 mg/kg pheno-
barbital, 0.01 mg/kg atropine, and 4 mg/kg ketamine in the
aseptic collecting room 30 minutes before specimen collec-
tion. In addition, 8–25 mL of bone marrow (0.6-1.0 mL/kg
of body weight) was collected from the right posterior su-
perior iliac spine according to conventional bone marrow
aspiration procedures. A total of 100 U/mL heparin was
added to the collecting tube as an anticoagulant. Following
current manufacturing best practices, mononuclear bone
marrow cells were isolated by Percoll (1.073 g/mL) centrifu-
gation and were allowed to adhere to a flask for 72 hours in
low glucose Dulbecco’s Modified Eagle’s Medium (Gibco-
Invitrogen) at 5% CO2 and 37°C, and the media were chan-
ged every 3 days. The cells with a strong positive signal for
the multipotential marker Oct 4 and Nanog were screened
for further cloning and culturing (Additional file 1: Figure
S1A). The cell phenotypes were assessed by flow cytometry.
The results indicated that CD34 and CD45 were negative,
and the positive rates of CD29 and CD44 were above 95%
(Additional file 1: Figure S1B). The ability of the cells to
Figure 1 Study protocol. A total of 60 patients with cerebral palsy with Gross Motor Function Classification System (GMFCS) levels III-V were
enrolled in this study. For the transplantation group, a total of 30 cerebral palsy patients received the autologous NSC-like cell transplantation and
rehabilitation treatments whereas 30 patients in the control group only received rehabilitation treatment. The study protocol is shown. Motor
ability was assessed using the Gross Motor Function Measure questionnaire-88. Language ability was measured using the Gesell questionnaire. All
of the assessments were conducted by a specifically assigned person, and the assessment results were recorded in the case report. A safety
evaluation was performed during the 6-month follow-up to detect instances of death, any serious clinical events, abnormal
electroencephalogram results, and neuroimaging complications.
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confirmed in vitro following the criteria of the 2006 Inter-
national Society of Cellular Therapy [21]. At 70%–80%
confluence, the cells were detached and replated at 5 × 106/
175 cm2 in culture to process for neural differentiation and
confirm negativity for endotoxin, hepatitis C virus, hepatitis
B virus, HIV, syphilis, fungus, Myco plasma species, and
Chlamydia before infusion. A G-banding karyotype analysis
was performed to confirm the absence of chromosomal
aberrations in the final cellular product. The MSCs were
continuously cultured without cryopreservation and were
thawed before transplantation. Supplementary methods
were shown in more detail (see Additional file 1).
Autologous NSC-like cells induction and differentiation
At 30%-40% confluence, a combination of 20 ng/ml re-
combinant human FGF basic (bFGF) and 10 nM retinoicacid was added to the medium for 12 hours to transform
the MSCs, and the differentiation capacity was evaluated
after 14 days [14]. Growth curves were drawn to assess
the proliferation ability of the MSCs and the trans-
formed cells (Figure 2A). In total, 1 × 104 of the trans-
formed cells were collected to prepare slices for
immunofluorescence staining, and 50%–70% of the cells
expressed Nestin and Tuj-1 (Figure 2B). A total of 1 ×
106 cells were co-labelled with antibodies against Nestin
(BD Pharmingen) and Tuj-1 (Abcam) , Sox2 (Abcam) or
Sox1 (Santa Cruz). According to the flow cytometry ana-
lysis, 66.83%, 90.92% and 64.71% of the induced cells
expressed both Nestin and Tuj-1, Sox2 and Sox1, re-
spectively (Figure 2B). These results suggest that the
MSCs differentiated into NSC-like cells. The NSC-like
cells were detached, washed three times in saline, re-
suspended in saline with 5% human albumin and filtered
Figure 2 MSCs can be induced to differentiate into NSC-like cells and exhibit multipotency by generating progenies of different neural
lineages in vitro. (A) During differentiation, MSCs develop the properties of neural stem cells (NSCs). The induced cells were observed in the
bright fields after 0.5 days and after 14 days. The growth curves of the MSCs and the NSC-like cells, which were obtained by enumerating the
cells at each time point under a haemocytometer, are shown (n=3; the calculated doubling times were 20 hours and 40 hours, respectively).
(B) After induction, the NSC-like cells were fixed, and immunofluorescence was used to detect the expression of Nestin and Tuj-1. The cells were
counterstained using DAPI. The scale bar is 10 μm. To assess the induction efficiency, the cells were co-labelled with antibodies against Nestin
and Tuj-1, Sox-2 or Sox1, and the proportions of double-positive cells were 66.83%, 90.92% and 64.71%, respectively. The tests were repeated
three times. (C) To determine whether the induced NSC-like cells could differentiate into both neurons and glia cells, MSCs were induced for
14 days under the same conditions and stained using antibodies against neuron- and glial cell-specific proteins. The scale bar is 10 μm.
Chen et al. Journal of Translational Medicine 2013, 11:21 Page 4 of 11
http://www.translational-medicine.com/content/11/1/21in a 100-μm nylon filter. Approximately 100 μl of this
solution was used for safety and viability tests. No
chromosomal aberrations or increased telomerase activ-
ity was found for the induced NSC-like cells. In addition,
a high cell viability (>90%) and the negative microbio-
logical results ensured the quality of the cells before the
transplantations. To determine whether the inducedNSC-like cells could differentiate into different neural
lineages, MSCs were induced for 14 days under the same
conditions and were stained using antibodies against
Tuj-1 (Abcam), NeuN (Abcam), Tau (Abcam), Nestin
(Santa Cruz), CD44 (Santa Cruz) and GFAP (Santa
Cruz). The induced cells expressed both neuron- and
glial cell-specific proteins (Figure 2C).
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The MSC-derived NSC-like cells (1.0 × 106) were implanted
subcutaneously into the flanks of nude mice or were trans-
planted intraspinally into the subarachnoid space of nude
mice. No tumour formation or other adverse events were
observed in mice after 3 months. The animal studies were
approved by the Institutional Animal Care and Use Commit-
tee of the Second Military Medical University in Shanghai,
China.
Cell transplantation therapy
Before the lumbar puncture, the patients fasted without
food and water. The patients were injected with pheno-
barbital sodium, atropine, and ketamine according to the
dose and usage guidelines before the collection of bone
marrow. When the patients fell asleep, a local anaes-
thetic was infiltrated under the skin and a spinal needle
was inserted between the lumbar vertebrae L3/L4 or L4/
L5 and pushed in until the needle traversed the dura
mater and the thin arachnoid membrane into the sub-
arachnoid space. The stylet from the spinal needle was
withdrawn, and drops of cerebrospinal fluid (up to 5 ml)
were collected. Then, 5 ml cell suspension, which con-
tained 1-2 × 107 of NSC-like cells, was gently injected
into the subarachnoid cavity through the spinal needle.
The opening pressure of the cerebrospinal fluid was
measured during specimen collection using a simple col-
umn manometer. The procedure ended by withdrawing
the needle while placing pressure on the puncture site.
The cell transplantation was administered at intervals of
3 weeks for two cycles. In addition, the patients in the
transplantation group received rehabilitation treatments
at the same time.
Observation indices
As the primary measurement, the motor and language
abilities of the patients were observed before treatment
and at 1, 3, and 6 months post-treatment. Motor ability
was assessed using the Gross Motor Function Measure
(GMFM-88 or GMFM) [22] questionnaire. An example
was shown in Additional file 1. Language ability was
measured using the Gesell questionnaire. The language
developmental quotient (LDQ) was determined using the
following formula: language developmental age/present
age × 100. All of the assessments were conducted by a
specifically assigned person. For the observer-blinded
design of the study, the patients were randomly arranged
before the tests, and the examiner was blinded to the
names and the grouping of patients. The assessment
results were recorded in the case reports.
The secondary measurement was patient survival and
the incidence of the following adverse events: (1) fever,
headache, allodynia, vomiting, infection, or otherreactions; (2) clinical seizures and/or epileptic discharges
on a serial electroencephalogram (EEG) at any time dur-
ing hospitalization; (3) new lesions in the skull according
to MRI at 6 months post-procedure; and (4) other clinic-
ally significant complications from the procedure during
the long-term folow-up.
Statistical analysis
The data were expressed as the mean ± S.E.M. The statis-
tical significance of the patient ages, GMFM scores and
language developmental quotients was detected using
the one-way ANOVA analysis, LSD test and two-tailed
Student’s t-test. The statistical significance of gender and
the GMFCS levels was detected using the chi-squared test.
The statistical analysis was performed using SPSS 11.0.
Results
Baseline characteristics of the patients
A total of 30 patients with cerebral palsy in GMFCS
levels III-V were enrolled in this study and were
included in the transplantation group. The group con-
sisted of 14 males and 16 females with a mean age of
5.53 ± 1.20 years (range, 1–32 years). An additional 30
patients with cerebral palsy were treated with conven-
tional methods and were included in the control group,
which consisted of 14 males and 16 females with a mean
age of 4.66 ± 1.31 years (range, 1–35 years). The baseline
characteristics of the patients in the two groups at the
study onset are shown in Tables 1–2. In addition, a com-
parison of the patient ages, LDQs and GMFM scores in
the two groups are shown in Figure 3. No significant dif-
ferences were found.
The MRI results from the skulls of patients with cere-
bral palsy can show a periventricular white matter injury
(PWMI), and the pathological findings can include peri-
ventricular leukomalacia and diffused dysmyelination
[23,24]. Prasad [25] studied 102 children 1–3 years of
age with cerebral palsy and found that 47.1% had a
PWMI in the skull based on MRI findings. In this study,
16 of the 30 patients (54.5%) in the transplantation
group had white matter injuries according to MRI.
Functional outcomes of motor development among the
two groups
The motor functions of the patients were observed and
evaluated using the GMFM scores before treatment and
at 1, 3, and 6 months post-treatment (Table 1). The
GMFM scores of all of the patients in the two groups
gradually increased during the 6 months post-treatment,
however, there were no significant differences in the
control group. In contrast, the GMFM scores in the
transplantation group at months 3 and 6 post-treatment
were significantly higher compared with the baseline
scores (P=0.011 and 0.001), whereas there were no
Table 1 Clinical characteristics of the 30 patients in the
transplantation group
No. Gender GMFCS stage Age (years) LDQ GMFM
1 Female V 1 72 36
2 Female III 3 31.7 176
3 Male III 4 28 189
4 Male III 4 92 185
5 Male V 3 100 50
6 Male IV 2 38 101
7 Male V 4.5 15 23
8 Male IV 4 26.8 115
9 Female V 3 75 42
10 Female IV 13 82 105
11 Female V 1.5 62 38
12 Male V 1 70 31
13 Female V 1 75 20
14 Male IV 2 90 63
15 Male III 4 98 191
16 Female IV 3 30 96
17 Male IV 21 80 82
18 Female III 2 98 120
19 Male IV 5 85 86
20 Female III 8 10 115
21 Female III 4 90 183
22 Female V 5 10 23
23 Female III 12 100 195
24 Male IV 2 98 83
25 Male V 1 15 12
26 Female III 6.5 90 193
27 Female III 4 92 196
28 Female IV 32 73 117
29 Female V 1 54 56
30 Male III 8.5 97 201
The clinical characteristics of the 30 patients in the transplantation group
before the cell transplantation treatment are shown. GMFCS: Gross Motor
Function Classification System levels; LDQ: language developmental quotient;
GMFM: Gross Motor Function Measurement scores.
Table 2 Clinical characteristics of the 30 patients in the
control group
No. Gender GMFCS stage Age (years) LDQ GMFM
1 Female V 1 72 36
2 Female III 2.5 35 183
3 Male III 3.5 28 198
4 Male III 4 92 211
5 Male V 2 100 35
6 Male V 2 38 23
7 Male V 4.5 15 33
8 Male IV 3.5 27 110
9 Female V 2 75 51
10 Female IV 2.5 82 99
11 Male IV 1 60 80
12 Female III 15 95 201
13 Female III 1 62 135
14 Male IV 5 86 110
15 Female IV 2.5 95 98
16 Male IV 21 98 135
17 Male IV 35 82 90
18 Male IV 9 80 112
19 Female V 4 12 30
20 Female V 1 23 43
21 Male V 1.7 25 45
22 Female V 1 30 50
23 Female III 1.5 80 146
24 Female V 3 39 25
25 Male IV 2.5 96 99
26 Male V 2.6 100 28
27 Female III 2 86 100
28 Female V 1 65 45
29 Male III 1.5 85 125
30 Male V 1 64 43
The clinical characteristics of the 30 patients in the control group are shown.
GMFCS: Gross Motor Function Classification System levels; LDQ: language
developmental quotient; GMFM: Gross Motor Function Measurement scores.
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post-treatment (P=0.265). The GMFM score increase
from baseline to month 6 post-treatment was 58.6 (95% CI:
25.8-91.4) in the transplantation group. This finding sug-
gests that there was a significant recovery effect in motor
function after the transplantation treatment. Additional
movie files were shown in more detail (see Additional file 2
and 3). In addition, we found that the GMFM scores at
months 3, and 6 post-treatment were significantly higher in
the transplantation group compared with those in the con-
trol group (P=0.003 and P<0.001, respectively). However,
there were no differences in the GMFM scores at month1 post-treatment between the two groups (P=0.089)
(Figure 4A). To evaluate the impact of NSC transplant-
ation in patients with different levels of cerebral palsy, we
divided the patients according to their GMFCS levels. The
results indicated that patients in the transplantation group
with levels IV and V had a better recovery of motor func-
tion (Figure 4B-D).
Functional outcomes of language development among
the two groups
The language abilities of the patients were observed be-
fore treatment and at 1, 3, and 6 months post-treatment.
The means of the language developmental quotients of
Figure 3 A comparison of the baseline characteristics of the patients in the two groups. (A) A comparison of the number of patients
according to the Gross Motor Function Classification System (GMFCS) levels in the transplantation (Trans) and control groups. Statistically
significant differences were detected using the chi-squared test. (B-D): A comparison of the mean ages (B), mean baseline Gross Motor Function
Measure (GMFM) scores (C) and mean baseline language developmental quotients (LDQs) (D) of the patients in the transplantation (Trans) and
control groups is shown. Statistically significant differences were detected between the groups using a Student t-test.
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ing the 6 months post-treatment (Figure 5). However, no
significant differences in the language developmental
quotients were observed at months 1, 3, and 6 post-
treatment when compared with the baseline quotients in
both groups (P>0.05 for all). In addition, we did not find
any significant differences in the language developmental
quotients at months 1, 3, and 6 post-treatment between
the two groups (P=0.751, 0.522 and 0.304, respectively).
This finding suggests that the recovery of language func-
tions was not accelerated in the transplantation group.
Adverse reactions in the transplantation group
No new neurological deficits were immediately identified
after NSC treatment. All of the patients in this study
were observed for more than 6 months after treatment.
None of the 60 patients experienced fever, headache,
allodynia, vomiting, or other serious adverse events that
were related to the experimental procedure. Follow-up
MRI evaluations did not show any significant anatomical
or structural changes that could indicate adverse events.
There was no evidence of any new ischemic, haemor-
rhagic, or neoplastic lesions. However, an increase in the
frequency of crying was reported in one patient butresolved spontaneously 2 days after the treatment with-
out any intervention. Other possible adverse effects or
complications in the control and transplantation groups
were evaluated, but no differences were observed in the
frequency of new-onset morbidities between the groups.
Discussion
Improvements in perinatal emergency medicine have
decreased the neonatal mortality rate, however, the inci-
dence of hypoxic ischemic encephalopathy and pre-
mature cerebral palsy have increased over time [1].
Conventional rehabilitation treatment for cerebral palsy
cannot improve the motor function of patients with
moderate-to-severe chronic cerebral palsy [5,6]. In this
study, we did not find any significant improvement in
the motor functions of the patients in the control group.
However, in the transplantation group, our data indi-
cated that the GMFM scores post-treatment were sig-
nificantly higher after 3 months compared with the
baselines scores, which suggests that the motor recovery
effects were accelerated in the transplantation group. In
addition, we found that patients in the transplantation
group with GMFCS levels IV and V had a better recov-
ery of motor functions. These results provide strong
Figure 4 A comparison of the kinetic Gross Motor Function Measure (GMFM) scores of the patients in the two groups. (A) A
comparison of the mean GMFM scores before treatment (0 months) and at 1, 3, and 6 months post-treatment for the patients in the
transplantation (Trans) and control groups. (B-D) A comparison of the mean GMFM scores for the patients with GMFCS levels III (B), IV(C) and V
(D) in the transplantation (Trans) and control groups. The data were expressed as the mean ± S.E.M. Statistically significant differences were
detected between the groups using a two-tailed Student’s t-test, * P<0.05, ** P<0.01, *** P<0.001. (E-F) Changes in the GMFM scores of the
patients in the transplantation (Trans) group (E) and in the control group (F) before and after treatment. Each line indicates the kinetic scores of
an individual patient.
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plantation for the treatment of cerebral palsy, especially
for moderate-to-severe chronic cerebral palsy.
The mechanism by which NSCs contribute to motor
function recovery remains controversial. Experimentshave demonstrated that transplanted NSCs exhibit
strong plasticity, can easily integrate with host cells and
can establish a stable synaptic connection and become
functional substituting nerve cells [26-28]. Additionally,
NSCs may produce neurotrophic factors that facilitate
Figure 5 A comparison of the kinetic language developmental quotients of the patients in the two groups. (A) A comparison of the
mean language developmental quotients before (0 months) and after treatment for the patients in the transplantation (Trans) and control
groups. (B-D) A comparison of the mean language developmental quotients for the patients with GMFCS levels III (B), IV(C) and V (D) in the
transplantation (Trans) and control groups. No statistically significant differences were detected between the groups using a two-tailed Student’s
t-test.
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gion [29-32]. Consistent with these findings, we found
that autologous NSC-like cells derived from MSCs could
differentiate into neuronal and glial lineages in vitro.
Our study was not designed to address the mechanism
of NSC functions in vivo, and future experiments are ne-
cessary to define the exact mechanism of therapeutic
cerebral repair by NSCs.
The safety of the NSC-based cell therapy is another ur-
gent problem. The risk for chromosomal aberrations,
neoplastic transformation, increased telomerase activity,
or both has been reported for human MSCs following sev-
eral passages in culture in experimental settings [33]. We
used early cultured MSCs (3–4 passage) that displayed
normal karyotypes and telomerase activity to induce NSC-
like cells. Before each treatment, we confirmed the safety
of induced NSC-like cells by telomerase activity evalu-
ation, karyotype analysis and microbiological detection.
To our knowledge, there are no clinical data that support
the development of neoplasms that are directly related toan autologous MSC inoculum [34,35]. In this study, we
evaluated the safety of MSCs and NSC-like cells in nude
mice, and no tumour formation or other complications
were found in a long-term (more than 3 months) study.
Moreover, allodynia was reported to be a risk of intrasp-
inal neural stem cell transplantation [30]. In this study, we
did not find any cases of allodynia or other adverse events
during the 6-month follow-up. Therefore, we confirmed
that the cells in our study were safe for the patients, how-
ever, more long-term follow-up studies may be necessary
to further confirm the safety of NSC-like cells.
In this study, we did not find any evidence of acceler-
ated recovery of language function in the transplantation
group. Language disorders in children with cerebral
palsy are categorized as asophia, anarthria and language
developmental delays [36], which are caused by a motor
disturbance of the speech organs due to brain injury.
Language recovery is affected by multiple factors [37].
The time period from 7–24 months after birth is import-
ant for establishing brain language signal pathways. In
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language training. Therefore, stem cells combined with
language training at an earlier stage may improve the
language ability of these patients.
The main limitations of this study include the small sam-
ple size and the lack of a randomised, double-blinded,
placebo-controlled design. However, we employed an ob-
server-blinded, controlled design to minimize measurement
bias. As shown in Figure 3, the baseline characteristics of
the patients from the two groups are well matched, and no
significant differences were found between the two groups
in the comparison of the patient ages, LDQs and GMFM
scores at the study onset. This study is the first reported
controlled clinical trial of NSC-like cells therapy for chronic
cerebral palsy, and our study provides strong clinical evi-
dence that supports stem cell transplantation for the treat-
ment of motor deficits related to cerebral palsy. Further
randomised clinical trials are necessary to establish the effi-
cacy of this procedure.
Conclusion
Our data indicates that the transplantation of MSC-derived
NSC-like cells is safe and effective for the treatment of
chronic cerebral palsy. Motor function, but not the lan-
guage quotient, indicated optimal improvement 3 months
after transplantation.
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